Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain binding antagonists

Molecular Cancer Therapeutics

Volumn 3, Issue 10, 2004, Pages 1289-1299

  Soriano, Jesus V ^a,d   Liu, Ningfei ^c   Gao, Yang ^a   Yao, Zhu Jun ^a   Ishibashi, Toshio ^b   Underhill, Charles ^c   Burke Jr , Terrence R ^a   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Social Insurance Central General Hospital   (Japan)

^c GEORGETOWN UNIVERSITY   (United States)

^d AMERICAN TYPE CULTURE COLLECTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; C 126; C 90; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MATRIGEL; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN SH2; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL COMPARTMENTALIZATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FETUS MEMBRANE; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; COLLAGEN; DISEASE PROGRESSION; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 2; GRB2 ADAPTOR PROTEIN; GROWTH SUBSTANCES; HUMANS; LAMININ; MODELS, CHEMICAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; PROTEOGLYCANS; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TETRADECANOYLPHORBOL ACETATE;

EID: 7444229834     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000;34:185-94.
2. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:1358-66.
3. Pepper MS. Positive and negative regulation of angiogenesis: from cell biology to the clinic. Vasc Med 1996;1:259-66.
4. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
5. Rosen EM, Lamszus K, Laterra J, Polverini PJ, Rubin JS, Goldberg ID. HGF/SF in angiogenesis. Ciba Found Symp 1997;212:215-26.
6. Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992;70:431-42.
7. Clark SG, Stern MJ, Horvitz HR. C. elegans cell-signaling gene sem-5 encodes a protein with SH2 and SH3 domains. Nature 1992;356:340-4.
8. Matuoka K, Shibata M, Yamakawa A, Takenawa T. Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries. Proc Natl Acad Sci U S A 1992;89:9015-9.
9. Buday L. Membrane-targeting of signaling molecules by SH2/SH3 domain-containing adaptor proteins. Biochim Biophys Acta 1999;1422: 187-204.
10. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363:15-6.
11. Pawson T, Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997;278:2075-80.
12. Rozakis-Adcock M, McGlade J, Mbamalu G, et al. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 1992;360:689-92.
13. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000; 19:5582-9.
14. Yamauchi T, Ueki K, Tobe K, et al. Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Endocr J 1998;45 Suppl:27-31.
15. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999;71:435-78.
16. Zhang S, Weinheimer C, Courtois M, et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest 2003;111:833-41.
17. Yamazaki T, Komuro I, Yazaki Y. Role of the renin-angiotensin system in cardiac hypertrophy. Am J Cardiol 1999;83:53-7H.
18. Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K. Signaling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 1994;9: 3545-55.
19. Saaristo A, Veikkola T, Tammela T, et al. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med 2002;196: 719-30.
20. Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP. Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling. Oncogene 1999;18:507-14.
21. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521-7.
22. Shono T, Kanetake H, Kanda S. The role of mitogen-activated protein kinase activation within focal adhesions in chemotaxis toward FGF-2 by murine brain capillary endothelial cells. Exp Cell Res 2001;264:275-83.
23. Stoletov KV, Ratcliffe KE, Terman BI. Fibroblast growth factor receptor substrate 2 participates in vascular endothelial growth factor-induced signaling. FASEB J 2002;16:1283-5.
24. Fournier TM, Kamikura D, Tang K, Park M. Branching tubulogenesis but not scatter of Madin-Darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. J Biol Chem 1996; 271:22211.
25. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
26. Dankort D, Maslikowski B, Warner N, et al. Grb2 and She adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol 2001; 21:1540-51.
27. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 1995;15:1110-22.
28. Cheng AM, Saxton TM, Sakai R, et al. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 1998;95:793-803.
29. Maina F, Casagranda F, Audero E, et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 1996;87:531-42.
30. Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene 2004;21:1800-11.
31. Dunican DJ, Doherty P. Designing cell-permeant phosphopeptides to modulate intracellular signaling pathways. Biopolymers 2001;60:45-60.
32. Fretz H, Furet P, Garcia-Echeverria C, Schoepfer J, Rahuel J. Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. Curr Pharm Des 2000;6:1777-96.
33. Yao ZJ, King CR, Cao T, et al. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem 1999;42:25-35.
34. Gao Y, Luo J, Yao ZJ, et al. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J Med Chem 2000;43:911-20.
35. Burke TR Jr, Smyth MS, Nomizu M, Otaka A, Roller PP. Preparation of fluoro- and hydroxy-4-phosphonomethyl-D,L-phenylalanine suitably protected for solid phase synthesis of peptides containing hydrolytically stable analogues of O-phosphotyrosine. J Org Chem 1993;58:1336-40.
36. Bandyopadhyay G, Sajan MP, Kanoh Y, et al. Glucose activates mitogen-activated protein kinase (extracellular signal-regulated kinase) through proline-rich tyrosine kinase-2 and the Glut1 glucose transporter. J Biol Chem 2000;275:40817-26.
37. Shi ZD, Wei CQ, Lee K, et al. Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands. J Med Chem 2004;47:2166-9.
38. Stahl SJ, Wingfield PT, Kaufman JD, et al. Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J 1997;326:763-72.
39. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992;99:683-90.
40. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-56.
41. Malinda, KM, Nomizu M, Chung M, et al. Identification of laminin α1 and β1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J 1999;13:53-62.
42. Murohara T, Witzenbichler B, Spyridopoulos I, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 1999;19:1156-61.
43. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 1985;42:469-77.
44. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Exp Cell Res 1993;204:356-63.
45. Grant DS, Kinsella JL, Fridman R, et al. Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J Cell Physiol 1992;153:614-25.
46. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
47. Liu N, Lapcevich RK, Underhill CB, et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 2001;61:1022-8.
48. Gay B, Suarez S, Weber C, et al. Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility. J Biol Chem 1999; 274:23311-5.
49. Atabey N, Gao Y, Yao ZJ, et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001;276:14308-14.
50. Carter-Su C, Smit LS. Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Recent Frog Horm Res 1998;53:61-82.
51. Ridyard MS, Robbins SM. Fibroblast growth factor-2-induced signaling through lipid raft-associated fibroblast growth factor receptor substrate 2 (FRS2). J Biol Chem 2003;278:13803-9.
52. Stein E, Cerretti DP, Daniel TO. Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells. J Biol Chem 1996;271:23588-93.
53. Jones N, Master Z, Jones J, et al. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 1999;274:30896-905.
54. Bornfeldt KE, Raines EW, Graves LM, Skinner MP, Krebs EG, Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci 1995; 766:416-30.
55. Boerner JL, Danielsen AJ, Lovejoy CA, et al. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis. Oncogene 2003;22:6679-89.
56. Zhang W, Samelson, LE. The role of membrane-associated adaptors in T cell receptor signaling. Semin Immunol 2000;12:35-41.
57. She HY, Rockow S, Tang J, et al. Wiskott-Aldrich syndrome protein is associated with the adapter protein Grb2 and the epidermal growth factor receptor in living cells. Mol Cell Biol 1997;8:1709-21.
58. Carlier MF, Nioche P, Broutin-L'Hermite I, et al. GRB2 links signaling to actin assembly by enhancing interaction of neural Wiskott-Aldrich syndrome protein (N-WASp) with actin-related protein (ARP2/3) complex. J Biol Chem 2000;275:21946-52S.
59. Wada T, Jagadeesh GJ, Nelson DL, Candotti F. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. Hum Gene Ther 2002;13:1039-46.
60. Scaplehorn N, Holmstrom A, Moreau V, Frischknecht F, Reckmann I, Way M. Grb2 and Nck act cooperatively to promote actin-based motility of Vaccinia virus. Curr Biol 2002;12:740-5.
61. Carlier MF, Le Clainche C, Wiesner S, Pantaloni D. Actin-based motility: from molecules to movement. BioEssays 2003;25:336-45.
62. Gendron RL. A plasticity for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Surv Ophthalmol 1999;44:184-5.
63. Beckmann MP, Cerretti DP, Baum P, et al. Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J 1994;13:3757-62.
64. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998;111:3621-31.
65. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356-62.
66. Mousa SA, Mousa AS. Angiogenesis inhibitors: current and future directions. Curr Pharm Des 2004;10:1-9.
67. Goodman L. Persistence-luck-Avastin. J Clin Invest 2004;113:934.
68. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
69. Millar A. Limitations of combination anti-angiogenesis and chemotherapy. Nat Rev Cancer 2003 [published online 6 Jan 2003]. Available from: http://www.nature.com/nrc/journal/v2/n10/corres/nrc905_fs.html